Eli Lilly Reported the Data from P-III (ACHIEVE-1) Trial Evaluating an Oral GLP-1, Orforglipron

Shots: The P-III (ACHIEVE-1) trial assessed orforglipron vs PBO in T2D adults (n=559) having inadequate glycemic control with diet & exercise alone; subjects started at 1mg QD, with dose escalation at every Q4W till assigned doses of 3, 12mg (via 1, 3 & 6mg), or 36mg (via 1, 3, 6, 12, & 24mg) Trial met…

ByPrince GiriApril 18, 2025

Zealand Pharma and Roche enter a ~$5.3B Deal to Co-Develop and Commercialize Petrelintide for Weight Management

Shots: Zealand Pharma & Roche will develop & market petrelintide & its products incl. petrelintide + CT-388 (Roche’s asset) in the US & EU for weight loss, with Roche obtaining exclusive marketing rights in the rest of the world Zealand will handle ~50% marketing in the US & EU with opt-in/out rights under specific…

ByRidhi RastogiMarch 12, 2025

Steffen-Sebastian Bolz, CSO of Aphaia Pharma Shares Insights from the P-II Study for Chronic Weight Management in Individuals with Obesity

Shots: Steffen shared the details of the first patient enrolled in the P-II study of Aphaia Pharma’s lead product APH-012 to induce weight loss in individuals with obesity He briefed the PharmaShots team about the study design of the P-II trial and also elaborated on the results from the P-I study The interview shows how…

BySenior EditorFebruary 27, 2023

Eli Lilly Reported the Data from P-III (ACHIEVE-1) Trial Evaluating an Oral GLP-1, Orforglipron

Zealand Pharma and Roche enter a ~$5.3B Deal to Co-Develop and Commercialize Petrelintide for Weight Management

Steffen-Sebastian Bolz, CSO of Aphaia Pharma Shares Insights from the P-II Study for Chronic Weight Management in Individuals with Obesity

Contact US

FOLLOW US